Antipodean Advisors Lowers stake in Insys Therapeutics Inc (INSY)

Insys Therapeutics Inc (INSY) : Antipodean Advisors reduced its stake in Insys Therapeutics Inc by 39.98% during the most recent quarter end. The investment management company now holds a total of 342,294 shares of Insys Therapeutics Inc which is valued at $6,287,941 after selling 227,991 shares in Insys Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Insys Therapeutics Inc makes up approximately 2.59% of Antipodean Advisors’s portfolio.

Other Hedge Funds, Including , Raymond James Financial Services Advisors sold out all of its stake in INSY during the most recent quarter. The investment firm sold 60,554 shares of INSY which is valued $1,112,377. Clinton Group Inc added INSY to its portfolio by purchasing 17,368 company shares during the most recent quarter which is valued at $319,050. Insys Therapeutics Inc makes up approx 0.01% of Clinton Group Inc’s portfolio.Vanguard Group Inc reduced its stake in INSY by selling 107,214 shares or 4.3% in the most recent quarter. The Hedge Fund company now holds 2,384,781 shares of INSY which is valued at $43,808,427.Tci Wealth Advisors boosted its stake in INSY in the latest quarter, The investment management firm added 15 additional shares and now holds a total of 3,545 shares of Insys Therapeutics Inc which is valued at $65,724. Insys Therapeutics Inc makes up approx 0.04% of Tci Wealth Advisors’s portfolio.

Insys Therapeutics Inc opened for trading at $14.43 and hit $14.655 on the upside on Thursday, eventually ending the session at $14.36, with a gain of 0.63% or 0.09 points. The heightened volatility saw the trading volume jump to 3,71,622 shares. Company has a market cap of $1,028 M.

On the company’s financial health, Insys Therapeutics Inc reported $0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.07. The company had revenue of $67.10 million for the quarter, compared to analysts expectations of $66.94 million. The company’s revenue was down -13.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.21 EPS.

Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Company’s lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *